This study was aimed at examining if the levels of human β-defensins (hBD1 and hBD2) in patients with inflammation can be used as biomarkers for infection or cancer, as well as to examine their diagnostic impact with regard to other conventional biomarkers of inflammation such as CRP or PCT. The gene discussed is DEFB1; the disease is cancer.